Skip to main content
Fig. 3 | The Journal of Headache and Pain

Fig. 3

From: Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study

Fig. 3

Most recent treatment episode: Unadjusted probability of remaining on treatment. Wilcoxon p-value < 0.0001. Note: sample size is reduced since extending the gap period changes the definition of an episode (e.g., distinct episodes with the same drug based on a 15-day gap may become a single episode and is excluded if the episode begins before June 25, 2020)

Back to article page